Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Patient guide

Stem-cell and perinatal therapies: a patient’s guide

A hopeful, practical guide to understanding the product, the evidence, and the person advising you.

By Olga Goodman, MD · Evidence through 25 September 2026

On this page

1. Why this subject deserves serious attention

Cell-based medicine is a very promising area of research. It is reasonable to be interested in new possibilities, especially after living with a difficult condition. But “stem-cell treatment” is not one treatment. The important question is whether a defined product has credible evidence for your particular problem—not whether the field as a whole sounds exciting. R01 R08

My approach is neither to recommend these treatments automatically nor to dismiss them automatically. A responsible opinion should explain the possible benefit, the uncertainty, the quality of the product, and the reasons for the recommendation.

2. What might actually be offered?

The proposal may involve blood-forming cells used in a specialized transplant program; mesenchymal stromal cells, often called MSCs; a mixed preparation obtained from bone marrow or fat; a cord or placental tissue product; or a processed placental extract. These are different categories. Cord blood is not the same as cord tissue, and an extract is not a transplant of living cells. R01 R06 R08

Ask for the exact name, manufacturer, source, contents, and route of administration. “Young cells,” “natural,” and “regenerative” do not provide that information.

3. Promise is not the same as a proven indication

Some cellular treatments have defined approved uses. That does not mean that every product from a similar source is approved or effective for arthritis, fatigue, skin aging, or another condition. A study of one disease cannot automatically answer a question about another. R01

Ask what the best relevant human study actually measured. Was there a comparison group? Was improvement short-lived or sustained? Did people continue other treatment? A testimonial may describe a real experience but cannot answer all these questions.

4. What result matters to you?

Name your goal in ordinary language: less disease activity, better walking, less pain, better organ function, or a specific change in appearance. These are not the same outcome. Feeling less pain does not by itself prove that damaged tissue has regrown.

A good consultation helps connect your goal to the evidence. It should also consider whether the diagnosis and the reason for your symptoms are sufficiently clear. Do not let a procedure package replace that assessment.

5. Who should advise you?

The person making an independent recommendation should understand your condition, the proposed product, the clinical research, relevant risks, and the limits of their own expertise. Being able to perform an injection is not the same as being able to judge a complex autoimmune disease or cell product.

Additional courses can be valuable, but a short course is not a substitute for the medical knowledge required for a complex decision. Different professionals can contribute to a good team. What matters is that the necessary disease-specific and product-specific expertise is actually present, with clear responsibility for your care.

6. What information should be available?

Ask how the product is identified, assessed for quality, stored, and traced to its source. Ask who has reviewed those documents. You should not have to audit a laboratory yourself, but the recommending team should not rely only on marketing material.

FDA registration and a listing on a clinical-trial website are not the same as FDA approval of a treatment. Ask for current documentation that applies to the actual product and proposed use. R05 R06

7. How should risk be discussed?

The risk depends on the product, route, your medical situation, and the setting. “Your own cells” does not make a procedure risk-free, and a donor source does not by itself make it inappropriate. Small studies cannot reliably rule out every uncommon or delayed problem. R05 R07

Clarify who will evaluate a complication and provide follow-up. Do not stop prescribed rheumatology treatment, steroids, blood thinners, or other medication on your own to receive an infusion. Medication decisions require a coordinated medical plan.

If serious symptoms occur after a procedure—such as breathing difficulty, chest pain, fainting, new neurologic symptoms, or a rapidly worsening painful swollen joint—seek urgent medical assessment rather than waiting for a routine website reply.

8. How are PRP and exosomes related?

PRP is a platelet-rich preparation, usually from your own blood; it is not stem-cell therapy. Extracellular vesicles, including the more specifically defined category of exosomes, are cell-derived particles rather than living cells. They are related to the broader idea of biological signaling and repair, but require separate evidence and quality assessment. R23

A result with PRP does not prove that an MSC product works, and a result with cells does not prove that a commercially marketed exosome product works.

9. What should you bring to an independent review?

Bring the diagnosis and the question you are trying to answer, the exact treatment proposal, a medication list, relevant prior records, the provider’s product information, and the studies used to support the recommendation. Use an agreed secure channel for private medical records, not public comments.

Ask for a written conclusion explaining the clinical target, applicable evidence, uncertainties, alternatives, and next step. A useful conclusion may support discussing a defined research option, request more information, recommend another specialist, or advise against the current proposal. It does not have to endorse a treatment to be valuable.

10. The main message

There is room for real optimism. The promise deserves a high standard of judgment, not a lower one. The best consultation should help you distinguish an interesting technology from a well-supported decision for you.

Olga Goodman, MD / Dr. Olga Goodman. This guide is educational, not individualized medical advice or clearance for a procedure. This personal publication is not a clinic portal or emergency service. Any private expert-opinion service is separate from clinic care and clinic accounts, is direct private pay, and is not billed to insurance. Original text requires author and source attribution when reused.

Sources

R01. FDA. Approved Cellular and Gene Therapy Products. Current product-specific register, checked September 25, 2026.

https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products

Regulator register; not a list of every procedure or tissue pathway. Access: Official product register.

R05. FDA. Important Patient and Consumer Information About Regenerative Medicine Therapies. 2021.

https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies

Historical consumer safety guidance. Its older statement about the only approved stem-cell products must NOT substitute for the current FDA register. Access: Official FDA consumer page.

R06. FDA. Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use. Guidance.

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimal

Regulatory framework; individual product classification requires its full facts. Access: Official guidance landing page and framework summary; not a line-by-line legal analysis of the full guidance.

R07. ISSCR. Guidelines for Stem Cell Research and Clinical Translation: Clinical Translation of Stem Cell-Based Interventions.

https://www.isscr.org/guidelines-online/clinical-translation-of-stem-cell-based-interventions

Primary professional framework for translation, manufacturing, research oversight, and informed consent. Access: Online primary guidelines.

R08. Viswanathan S, et al. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy position statement on nomenclature. Cytotherapy. 2019;21:1019–1024. doi:10.1016/j.jcyt.2019.08.002.

https://pubmed.ncbi.nlm.nih.gov/31526643/

Primary society nomenclature statement. Access: PubMed abstract and position-statement metadata.

R23. Figueroa-Valdés AI, et al. Clinical-grade extracellular vesicles derived from umbilical cord mesenchymal stromal cells: preclinical development and first-in-human intra-articular validation as therapeutics for knee osteoarthritis. J Nanobiotechnol. 2025;23:13. doi:10.1186/s12951-024-03088-x.

https://pubmed.ncbi.nlm.nih.gov/39806427/

EV research; not evidence that every product sold as exosomes is effective. Access: PubMed abstract.

Olga Goodman, MD · Rheumatology in Perspective · A RheumaView publication

Back to top

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: patient guideperinatal therapiesstem cells